tetano
Editor, Senior Moderator
Zhonghua Liu Xing Bing Xue Za Zhi
. 2021 Sep 10;42(9):1700-1708.
doi: 10.3760/cma.j.cn112338-20210323-00242.
[Progress in research of avian influenza virus and human monoclonal antibody and vaccines against H7N9 virus]
[Article in Chinese]
Y X Wang[SUP] 1 [/SUP], J X Li[SUP] 2 [/SUP], P Liu[SUP] 1 [/SUP], F C Zhu[SUP] 2 [/SUP]
Affiliations
Abstract
in English, Chinese
Avian influenza virus (AIV) is a kind of zoonotic virus which can cause acute respiratory infectious diseases. Since the report of the world's first human infection case of avian influenza A (H7N9) virus in China in 2013, close attention has been paid to the virus. AIV spreads widely around the world, and human infection with different types of AIV continues to occur, causing huge economic losses. At present, there are no specific treatment and drugs against the disease, and vaccination is considered as the most promising and effective method to control the human infection with AIV. So far, there are many kinds of veterinary and human vaccines for H7N9 AIV, among which four types of human H7N9 AIV vaccines have entered the clinical trial stage, including virus-like particles vaccine, attenuated live vaccine, inactivated vaccine and DNA vaccine, which have shown good safety and immunogenicity. However, the true efficacies of the AIV vaccines remain unknown because no human vaccines are currently available in the market. In addition, although the existing influenza vaccine has good safety and immunogenicity in the human population, there is no cross-antibody response to H7N9 AIV. This paper summarizes the research progress of AIV etiology and epidemiology, the occupational exposure population investigation, the infection prevention and control strategies, and H7N9 AIV vaccine and H7N9 AIV anthropogenic monoclonal antibody, and discuss the remained problems, challenges and future trends in the research of AVI to improve the understanding of the disease and the prevention and control of global spread of AIV.
. 2021 Sep 10;42(9):1700-1708.
doi: 10.3760/cma.j.cn112338-20210323-00242.
[Progress in research of avian influenza virus and human monoclonal antibody and vaccines against H7N9 virus]
[Article in Chinese]
Y X Wang[SUP] 1 [/SUP], J X Li[SUP] 2 [/SUP], P Liu[SUP] 1 [/SUP], F C Zhu[SUP] 2 [/SUP]
Affiliations
- PMID: 34814604
- DOI: 10.3760/cma.j.cn112338-20210323-00242
Abstract
in English, Chinese
Avian influenza virus (AIV) is a kind of zoonotic virus which can cause acute respiratory infectious diseases. Since the report of the world's first human infection case of avian influenza A (H7N9) virus in China in 2013, close attention has been paid to the virus. AIV spreads widely around the world, and human infection with different types of AIV continues to occur, causing huge economic losses. At present, there are no specific treatment and drugs against the disease, and vaccination is considered as the most promising and effective method to control the human infection with AIV. So far, there are many kinds of veterinary and human vaccines for H7N9 AIV, among which four types of human H7N9 AIV vaccines have entered the clinical trial stage, including virus-like particles vaccine, attenuated live vaccine, inactivated vaccine and DNA vaccine, which have shown good safety and immunogenicity. However, the true efficacies of the AIV vaccines remain unknown because no human vaccines are currently available in the market. In addition, although the existing influenza vaccine has good safety and immunogenicity in the human population, there is no cross-antibody response to H7N9 AIV. This paper summarizes the research progress of AIV etiology and epidemiology, the occupational exposure population investigation, the infection prevention and control strategies, and H7N9 AIV vaccine and H7N9 AIV anthropogenic monoclonal antibody, and discuss the remained problems, challenges and future trends in the research of AVI to improve the understanding of the disease and the prevention and control of global spread of AIV.